tetano
Editor, Senior Moderator
Pathogens. 2020 Apr 26;9(5). pii: E320. doi: 10.3390/pathogens9050320.
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs.
Neogi U[SUP]1,[/SUP][SUP]2[/SUP], Hill KJ[SUP]2,[/SUP][SUP]3[/SUP], Ambikan AT[SUP]1[/SUP], Heng X[SUP]4[/SUP], Quinn TP[SUP]4[/SUP], Byrareddy SN[SUP]5[/SUP], S?nnerborg A[SUP]2,[/SUP][SUP]3,[/SUP][SUP]6[/SUP], Sarafianos SG[SUP]7[/SUP], Singh K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]8[/SUP].
Author information
Abstract
Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.
KEYWORDS:
COVID-19; MERS-CoV; RNA polymerase; SARS-CoV; SARS-CoV-2; coronavirus; nsp12
PMID:32357471DOI:10.3390/pathogens9050320
Feasibility of Known RNA Polymerase Inhibitors as Anti-SARS-CoV-2 Drugs.
Neogi U[SUP]1,[/SUP][SUP]2[/SUP], Hill KJ[SUP]2,[/SUP][SUP]3[/SUP], Ambikan AT[SUP]1[/SUP], Heng X[SUP]4[/SUP], Quinn TP[SUP]4[/SUP], Byrareddy SN[SUP]5[/SUP], S?nnerborg A[SUP]2,[/SUP][SUP]3,[/SUP][SUP]6[/SUP], Sarafianos SG[SUP]7[/SUP], Singh K[SUP]1,[/SUP][SUP]2,[/SUP][SUP]3,[/SUP][SUP]8[/SUP].
Author information
Abstract
Coronaviruses (CoVs) are positive-stranded RNA viruses that infect humans and animals. Infection by CoVs such as HCoV-229E, -NL63, -OC43 and -HKU1 leads to the common cold, short lasting rhinitis, cough, sore throat and fever. However, CoVs such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), and the newest SARS-CoV-2 (the causative agent of COVID-19) lead to severe and deadly diseases with mortality rates ranging between ~1 to 35% depending on factors such as age and pre-existing conditions. Despite continuous global health threats to humans, there are no approved vaccines or drugs targeting human CoVs, and the recent outbreak of COVID-19 emphasizes an urgent need for therapeutic interventions. Using computational and bioinformatics tools, here we present the feasibility of reported broad-spectrum RNA polymerase inhibitors as anti- SARS-CoV-2 drugs targeting its main RNA polymerase, suggesting that investigational and approved nucleoside RNA polymerase inhibitors have potential as anti-SARS-CoV-2 drugs. However, we note that it is also possible for SARS-CoV-2 to evolve and acquire drug resistance mutations against these nucleoside inhibitors.
KEYWORDS:
COVID-19; MERS-CoV; RNA polymerase; SARS-CoV; SARS-CoV-2; coronavirus; nsp12
PMID:32357471DOI:10.3390/pathogens9050320